Conduit Pharmaceuticals Receives Further Patent Approval For Its Lead Asset Targeting Autoimmune Diseases

NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 09, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals", "Conduit" or the “Company”) today announces that the Korean Intellectual Property Office (KIPO) has granted the composition of matter patent for its lead asset, AZD1656, a Glucokinase Activator targeting autoimmune diseases. This approval follows recent grants in the U.S., Japan and Australia and further strengthens Conduit's global intellectual property position as it advances out-licensing discussions. Notably, South Korea is often commercially partnered with Japan in licensing and distribution arrangements by major Western pharmaceutical companies, making this an important strategic milestone in expanding Conduit’s reach across a highly valuable Asia-Pacific pharmaceutical region.

Read more at globenewswire.com